| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/S41379-018-0038-2 |
| P698 | PubMed publication ID | 29572500 |
| P50 | author | M. Carmen Chillón | Q73432002 |
| Alberto Orfao | Q89543246 | ||
| Enrique Colado | Q50236817 | ||
| Jacques Van Dongen | Q60655923 | ||
| P2093 | author name string | Daniel Rivera | |
| Mojca Jongen-Lavrencic | |||
| Carlos Fernández | |||
| Marcos González | |||
| Isabel Recio | |||
| Sergio Matarraz | |||
| Andrea Mayado | |||
| María Belén Vidriales | |||
| Teresa Caballero-Velázquez | |||
| Antonio López | |||
| Paloma Bárcena | |||
| Susana Barrena | |||
| María Laura Gutiérrez | |||
| Ana Yeguas Bermejo | |||
| Aránzazu García Mateo | |||
| Carlos Salvador Osuna | |||
| Cristina De Ramón Sánchez | |||
| Gloria García-Donas | |||
| Javier Sánchez-Real | |||
| Luis García Alonso | |||
| Monique Bourgeois García | |||
| Oliver Gutiérrez | |||
| Pilar Leoz | |||
| Vincent Van Der Velden | |||
| P2860 | cites work | EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes | Q24604581 |
| Marked basophilia in acute promyelocytic leukaemia treated with all-trans retinoic acid: molecular analysis of the cell origin of the basophils | Q72695767 | ||
| Severe hemorrhagic complications during remission induction therapy for acute promyelocytic leukemia: incidence, risk factors, and influence on outcome | Q79619548 | ||
| Predictive factors of bleeding and thrombosis during induction therapy in acute promyelocytic leukemia-a single center experience in 34 patients | Q81770481 | ||
| Evidence for basophilic differentiation of acute promyelocytic leukaemia cells during arsenic trioxide therapy | Q82737964 | ||
| Flow cytometry rapidly identifies all acute promyelocytic leukemias with high specificity independent of underlying cytogenetic abnormalities | Q82968569 | ||
| How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia | Q27022521 | ||
| The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia | Q27853375 | ||
| Expression and localization of ecto-nucleotide pyrophosphatase/phosphodiesterase I-1 (E-NPP1/PC-1) and -3 (E-NPP3/CD203c/PD-Ibeta/B10/gp130(RB13-6)) in inflammatory and neoplastic bile duct diseases | Q28255521 | ||
| Identification of a phosphodiesterase I/nucleotide pyrophosphatase-related gene mRNA in rat vascular smooth muscle cells by the differential display approach | Q28576171 | ||
| The role of mast cells and basophils in inflammation | Q33940573 | ||
| Early haemorrhagic morbidity and mortality during remission induction with or without all-trans retinoic acid in acute promyelocytic leukaemia | Q34508552 | ||
| Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis | Q34523534 | ||
| Acute promyelocytic leukemia: from highly fatal to highly curable | Q34755208 | ||
| Pathogenesis and management of the bleeding diathesis in acute promyelocytic leukaemia. | Q35205511 | ||
| Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. | Q35561038 | ||
| Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid | Q37216174 | ||
| New paradigms in basophil development, regulation and function | Q37686073 | ||
| The pathogenesis and management of the coagulopathy of acute promyelocytic leukaemia | Q37952402 | ||
| Bleeding and thrombosis in acute promyelocytic leukemia | Q38006876 | ||
| What is the standard regimen for patients with acute promyelocytic leukemia? | Q38204310 | ||
| Thrombo-hemorrhagic deaths in acute promyelocytic leukemia | Q38214955 | ||
| Understanding the molecular pathogenesis of acute promyelocytic leukemia | Q38218357 | ||
| The coagulopathy in acute promyelocytic leukaemia--what have we learned in the past twenty years | Q38218358 | ||
| Acute promyelocytic leukemia: what is the new standard of care? | Q38238284 | ||
| The immunophenotype of mast cells and its utility in the diagnostic work-up of systemic mastocytosis | Q38266219 | ||
| What's new in the pathogenesis of the coagulopathy in acute promyelocytic leukemia? | Q38694592 | ||
| Predictors of thrombohemorrhagic early death in children and adolescents with t(15;17)-positive acute promyelocytic leukemia treated with ATRA and chemotherapy | Q38735007 | ||
| Prognostic factors in acute promyelocytic leukemia: strategies to define high-risk patients | Q38752325 | ||
| Current management of newly diagnosed acute promyelocytic leukemia | Q38809825 | ||
| Stepwise discriminant function analysis for rapid identification of acute promyelocytic leukemia from acute myeloid leukemia with multiparameter flow cytometry | Q40115647 | ||
| Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. | Q40429557 | ||
| Prophylaxis of symptoms of hyperhistaminemia after the treatment of acute promyelocytic leukemia with all-trans retinoic acid | Q40567068 | ||
| Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens | Q44437398 | ||
| Administration of ATRA to newly diagnosed patients with acute promyelocytic leukemia is delayed contributing to early hemorrhagic death. | Q44572291 | ||
| Significance of fibrinogen, D-dimer, and LDH levels in predicting the risk of bleeding in patients with acute promyelocytic leukemia | Q44674591 | ||
| Brief report: severe symptoms of hyperhistaminemia after the treatment of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid) | Q44833068 | ||
| Early death in acute promyelocytic leukemia (APL) in French centers: a multicenter study in 399 patients | Q45021199 | ||
| FLT3-activating mutations are associated with poor prognostic features in AML at diagnosis but they are not an independent prognostic factor. | Q47418242 | ||
| Clinical bleeding events and laboratory coagulation profiles in acute promyelocytic leukemia. | Q53194151 | ||
| Targeted Therapy Alone for Acute Promyelocytic Leukemia. | Q53783512 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | leukemia | Q29496 |
| acute promyelocytic leukemia | Q612108 | ||
| cell fate commitment | Q14860192 | ||
| P304 | page(s) | 1318-1331 | |
| P577 | publication date | 2018-03-23 | |
| P1433 | published in | Modern Pathology | Q15724578 |
| P1476 | title | Basophil-lineage commitment in acute promyelocytic leukemia predicts for severe bleeding after starting therapy | |
| P478 | volume | 31 |
Search more.